Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00940225 · OUTCOME

Progression Free Survival (PFS) - Throughout the Study

Study of Cabozantinib (XL184) in Adults With Advanced Malignancies · Source last updated 2024-04-25

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
Inter-Quartile Range
Time frame
From initial dose through final study visit up to 44 months

What was measured

Progression-free survival (PFS) from first dose throughout the study was estimated for all subjects (safety population) using a piecewise method.

Groups in this outcome

CRPC

cabozantinib, 100 mg, po QD

Melanoma

cabozantinib, 100 mg, po QD

NSCL

cabozantinib, 100 mg, po QD

Pancreatic Cancer

cabozantinib, 100 mg, po QD

Gastric/GEJ

cabozantinib, 100 mg, po QD

Hepatocellular Carcinoma

cabozantinib, 100 mg, po QD

SCLC

cabozantinib, 100 mg, po QD

Ovarian Cancer

cabozantinib, 100 mg, po QD

Metastatic Breast Cancer

cabozantinib, 100 mg, po QD

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
CRPC171
Melanoma77
NSCL60
Pancreatic Cancer20
Gastric/GEJ21
Hepatocellular Carcinoma41
SCLC21
Ovarian Cancer70
Metastatic Breast Cancer45

Reported measurements

Source class 1
Values in months · Interval/dispersion: Inter-Quartile Range
GroupValueSpreadLowerUpperComment
CRPC6.8Not reported3.99.7Not reported
Melanoma2.8Not reported1.46.9Not reported
NSCL4.0Not reported1.45.7Not reported
Pancreatic Cancer2.7Not reported1.35.5Not reported
Gastric/GEJ1.4Not reported1.3NAUnable to estimate as number of events is too low.
Hepatocellular Carcinoma5.2Not reported3.69.3Not reported
SCLC3.4Not reported1.48.2Not reported
Ovarian Cancer5.5Not reported2.711.0Not reported
Metastatic Breast Cancer4.3Not reported1.48.1Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        3.9
        upper Limit
        9.7
        value
        6.8
      2. group Id
        OG001
        lower Limit
        1.4
        upper Limit
        6.9
        value
        2.8
      3. group Id
        OG002
        lower Limit
        1.4
        upper Limit
        5.7
        value
        4.0
      4. group Id
        OG003
        lower Limit
        1.3
        upper Limit
        5.5
        value
        2.7
      5. comment
        Unable to estimate as number of events is too low.
        group Id
        OG004
        lower Limit
        1.3
        upper Limit
        NA
        value
        1.4
      6. group Id
        OG005
        lower Limit
        3.6
        upper Limit
        9.3
        value
        5.2
      7. group Id
        OG006
        lower Limit
        1.4
        upper Limit
        8.2
        value
        3.4
      8. group Id
        OG007
        lower Limit
        2.7
        upper Limit
        11.0
        value
        5.5
      9. group Id
        OG008
        lower Limit
        1.4
        upper Limit
        8.1
        value
        4.3
denoms
  1. counts
    1. group Id
      OG000
      value
      171
    2. group Id
      OG001
      value
      77
    3. group Id
      OG002
      value
      60
    4. group Id
      OG003
      value
      20
    5. group Id
      OG004
      value
      21
    6. group Id
      OG005
      value
      41
    7. group Id
      OG006
      value
      21
    8. group Id
      OG007
      value
      70
    9. group Id
      OG008
      value
      45
    units
    Participants
description
Progression-free survival (PFS) from first dose throughout the study was estimated for all subjects (safety population) using a piecewise method.
dispersion Type
Inter-Quartile Range
groups
  1. description
    cabozantinib, 100 mg, po QD
    id
    OG000
    title
    CRPC
  2. description
    cabozantinib, 100 mg, po QD
    id
    OG001
    title
    Melanoma
  3. description
    cabozantinib, 100 mg, po QD
    id
    OG002
    title
    NSCL
  4. description
    cabozantinib, 100 mg, po QD
    id
    OG003
    title
    Pancreatic Cancer
  5. description
    cabozantinib, 100 mg, po QD
    id
    OG004
    title
    Gastric/GEJ
  6. description
    cabozantinib, 100 mg, po QD
    id
    OG005
    title
    Hepatocellular Carcinoma
  7. description
    cabozantinib, 100 mg, po QD
    id
    OG006
    title
    SCLC
  8. description
    cabozantinib, 100 mg, po QD
    id
    OG007
    title
    Ovarian Cancer
  9. description
    cabozantinib, 100 mg, po QD
    id
    OG008
    title
    Metastatic Breast Cancer
param Type
MEDIAN
reporting Status
POSTED
time Frame
From initial dose through final study visit up to 44 months
title
Progression Free Survival (PFS) - Throughout the Study
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice